Skip to main content
. 2022 Jun 21;10(6):e004226. doi: 10.1136/jitc-2021-004226

Table 1.

Summary of available biomarker results

PD-L1 DNA-Seq
(FoundationOne CDx)		 NanoString
(TIS)		 Digital IHC (CD8) Multiplex IHC RNA-Seq Flow
Cytometry		 Cytokine Profiling
(n=21)		 Targeted DNA-Seq (ctDNA)
Sample number, n 477 443
(TMB, 414)		 433 419 339 395 Baseline, 409;
week 4, 405		 Baseline, 511;
week 4, 479		 Baseline, 481;
week 8, 440
% of intention-to-treat population
(N=532)		 90 83
(TMB, 78)		 81 79 64 74 Baseline, 77;
week 4,
76		 Baseline, 96;
week 4, 90		 Baseline, 90;
week 8, 83

All numbers refer to baseline samples, unless otherwise indicated.

CD, cluster of differentiation; ctDNA, circulating tumor DNA; DNA-seq, DNA sequencing; IHC, immunohistochemistry; PD-L1, programmed death ligand 1; RNA-seq, RNA sequencing; TIS, T-cell-inflamed signature; TMB, tumor mutational burden.